

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>DEKKERS MARIJN E</u> (Last) (First) (Middle) <u>C/O QUANTERIX CORPORATION,</u> <u>900 MIDDLESEX TURNPIKE</u> (Street) <u>BILLERICA MA 01821</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Quanterix Corp [QTRX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/02/2020</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/02/2020		A		2,270 ⁽¹⁾	A	\$0.00	6,810 ⁽²⁾	D	
Common Stock								27,619 ⁽³⁾	I	Held by Novalis LifeSciences Investments I, L.P. ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (Right to Buy)	\$23.12	01/02/2020		A		7,900 ⁽⁵⁾		12/31/2020	01/02/2030	Common Stock	7,900	7,900	D	

Explanation of Responses:

- Represents restricted stock units that vest as to 100% of the shares on December 31, 2020 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
- Includes 2,270 restricted stock units.
- Reflects the portion of the 117,378 shares of the Issuer's common stock held by Novalis LifeSciences Investments I, L.P. (the "Fund") in which the Reporting Person has a pecuniary interest.
- The Fund owns an aggregate of 117,378 shares of common stock of the Issuer. The Reporting Person has sole voting and investment control over all of the shares owned by the Fund and has a pecuniary interest in 27,619 of the shares.
- Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy.

Remarks:

/s/ Brian Keane, as Attorney-in-Fact 01/06/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.